NeOnc Technologies (Nasdaq: $NTHI) will host an investor call on Aug. 12 at 5:30 a.m. PT / 8:30 a.m. ET to discuss topline Phase 2a results for intranasal NEO100™ in recurrent or progressive IDH1-mutant high-grade glioma. The call will cover efficacy, safety and planned regulatory next steps. Webcast: investors.neonc.com or webcaster5.com/Webcast/Page/… #NTHI #NEO100 #Biotech investors.neonc.com/news-rel…

NeOnc has received detailed, constructive and actionable FDA feedback regarding the CMC development of NEO212 and its planned transition from a capsule to a tablet for late-stage clinical development. The Company is incorporating the guidance into an updated development plan. Read the full press release below! #NeOncTechnologies #NEO212 #ClinicalDevelopment #Oncology #BrainCancer #CNSCancer #Biotechnology #FDA #NTHI investors.neonc.com/news-rel…

NeOnc is pleased to announce that the Department of Health – Abu Dhabi has granted IND status for NEO212, our orally administered perillyl alcohol-temozolomide conjugate being developed for patients with aggressive brain tumors. This milestone follows the successful completion of the Phase 1 dose-escalation portion of the NEO212 clinical program. The UAE clearance marks an important international step as NeOnc advances NEO212 toward Phase 2 development, while continuing discussions with the U.S. FDA. #NeOnc #NEO212 #Glioblastoma #BrainCancer #CNSCancer #Biotech #ClinicalTrials #Oncology #UAE #Phase2 #Nasdaq investors.neonc.com/news-rel…

NeOnc is pleased to share that Maxim Group has initiated coverage with a Buy rating and a $20 price target in its analyst report! We are proud to see continued recognition of our mission to advance innovative therapies for patients facing some of the most difficult-to-treat brain cancers. Read the analyst report: investors.neonc.com/static-f…

NeOnc Technologies (Nasdaq: NTHI) CEO Amir Heshmatpour continues to deepen his alignment with shareholders, investing nearly $1M of personal capital over the past year — including $500K+ in recent open-market purchases. This comes at a pivotal moment for NeOnc, as the company advances toward key clinical and regulatory milestones. Read the full press release. investors.neonc.com/news-rel… #NeOnc #NTHI #Biotech #Healthcare #Investing #BrainCancerResearch

NeOnc Technologies $NTHI recently announced approximately $300,000 in open-market stock purchases by Chairman & CEO Amir Heshmatpour, reinforcing management’s alignment with shareholders and confidence in the Company’s long-term strategy. investors.neonc.com/news-rel…

NeOnc Technologies | One Year on NASDAQ (NTHI) | Progress, Pipeline & What’s Next One year after NeOnc Technologies' listing on NASDAQ under the ticker NTHI, NeOnc reflects on key clinical and regulatory milestones achieved as a public company. This video highlights progress across the pipeline, reinforces the company’s strategic positioning, and looks ahead to the next phase of execution, bringing innovative therapies closer to patients who need them most. piped.video/watch?v=uxcjTkb2… #NTHI #NeOnc #GBM

NeOnc Technologies Holdings Inc NTHI will host a live investor conference call and webcast on March 4, 2026 at 6:00 a.m. PT / 9:00 a.m. ET to present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial. The discussion will include: • Safety and toxicity findings • Dose-escalation observations • Pharmacokinetic data • Planned regulatory next steps 📅 March 4, 2026 ⏰ 6:00 a.m. PT / 9:00 a.m. ET 🔗 Live webcast: webcaster5.com/Webcast/Page/… We look forward to sharing these important clinical updates with the investment community. investors.neonc.com/news-rel…

Top Entrepreneurs Going into 2026 via @USATODAY We’re thrilled to celebrate our CEO, Amir Heshmatpour, being featured in USA Today’s list of Top Entrepreneurs Going Into 2026 — a testament to visionary leadership and bold innovation shaping the future of biotech. 👏 Congratulations, to Amir & NeOnc! Here’s to a year of breakthrough science, meaningful progress, and continued impact for patients worldwide. #Leadership #Entrepreneurship #Biotech #Innovation #2026Vision #Neonc usatoday.com/story/special/c…

NeOnc has secured a strategic PIPE investment led by a $10M commitment from Cinctive Capital Management, with total gross proceeds expected to reach ~$16M. This investment reflects strong institutional confidence in NeOnc’s mission, science, and proprietary CNS delivery platforms. It supports the acceleration of clinical programs focused on bypassing the blood-brain barrier to treat CNS cancers. #NeOnc #NTHI #CNSCancer #BiotechInvesting #ClinicalTrials investors.neonc.com/news-rel…

This video highlights pediatric DIPG patients in China receiving investigational NEO100-03 intranasal therapy following prior standard treatments. Their stories underscore the urgent unmet need in pediatric brain cancer and the importance of continued clinical research. #NeOnc #PediatricCancer #BrainCancerResearch #DIPG #ClinicalResearch

Updated clinical data for intranasal NEO100 show continued durable responses in recurrent IDH1-mutant astrocytoma 🧠 • 24% radiographic remission • 44% PFS-6 • 36% alive ≥18 months • No significant toxicity A promising step forward for patients with limited options. Read the full press release below: investors.neonc.com/news-rel…

NeOnc Technologies (Nasdaq: $NTHI) announces new findings showing that ultrasound enhances the potency of NEO100 in treating primary and metastatic brain tumors. A breakthrough at the intersection of AI, oncology, and precision medicine. #NTHI #AIinMedicine #Biotech #CancerResearch #NeOnc #NEO100 investors.neonc.com/news-rel…

🚨 NeOnc completes enrollment in its pivotal NEO100 Phase 2a trial for IDH1-mutant recurrent glioma. Preliminary data coming Q2 2026. This milestone follows positive results from a 24-patient cohort shared on the Nov. 12 investor call. investors.neonc.com/news-rel… #NTHI #NEO100 #Biotech #Glioma #CNS

NeOnc Technologies (NTHI) is honored to announce that His Highness Sheikh Nahyan bin Zayed Al Nahyan has assumed the role of Executive Chairman of NuroMENA, our Middle East subsidiary — marking a new era in UAE–US collaboration against brain cancer. 🇦🇪🇺🇸🧠 investors.neonc.com/news-rel…

As a Director of the biotech company @NeOncTechInc bringing brain cancer treatments to market, this independent analysis is spot on: (1) "NeOnc is at a key inflection point from a survival story to a growth story" Kudos to the team! seekingalpha.com/article/482…

The brain has a natural barrier that blocks most drugs from reaching where they are needed. @NeOncTechInc is changing that. If you missed this episode, you can watch it now at HealthUncensoredTV.com. Follow us and @drdrew to stay on top of everything health.

We’re going on @HUwithDrDrew! 🎉 📅 Sept 25 | ⏰ Airs nationwide at 8 AM| Lifetime TV Hear from Dr. Chen (Founder & CEO) & Amir Heshmatpour (President & Executive Chairman) about how @NeOncTechInc is redefining brain cancer treatment. Plus, Adeline, a remarkable NEO-100 patient, will share her inspiring journey and the impact of NeOnc’s therapies. 📺 Tune in for a powerful conversation of science, hope, and innovation. #NeOnc #DrDrew #HealthUncensoredwithdrdrew #BrainCancer #CancerCare #Innovation #GBM